The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma.
A Charloux, E Quoix, N Wolkove, D Small… - International journal …, 1997 - academic.oup.com
… Higgins IT, Wynder E L. Reduction in risk of lung cancer among exsmokers with particular
… 80 Theros E G. Varying manifestations of peripheral pulmonary neoplasms: a radiologic-…
… 80 Theros E G. Varying manifestations of peripheral pulmonary neoplasms: a radiologic-…
Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings
…, A Gangi, D Charneau, X Ducroq, R Kessler, E Quoix… - Radiographics, 2002 - pubs.rsna.org
… (e) Photograph of a cut specimen of the resected middle lobe (axial section) shows the …
(e) Photograph of a cut specimen of the resected middle lobe (axial section) shows the …
(e) Photograph of a cut specimen of the resected middle lobe (axial section) shows the …
[HTML][HTML] From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French …
…, P Lefebure, F Laurent, S Liebart, O Molinier, E Quoix… - Annals of oncology, 2013 - Elsevier
Background Despite advances in cancer therapy, mortality is still high except in early-stage
tumors, and screening remains a challenge. The randomized National Lung Screening Trial (…
tumors, and screening remains a challenge. The randomized National Lung Screening Trial (…
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
…, B Besse, HJM Groen, PJ Souquet, E Quoix… - The Lancet …, 2016 - thelancet.com
Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein
kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown …
kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown …
Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non–small-cell lung cancer
…, D Moro-Sibilot, S Chevret, E Quoix… - Journal of clinical …, 2002 - ascopubs.org
… Elisabeth Quoix … Alain Depierre, Bernard Milleron, Denis Moro-Sibilot, Sylvie Chevret,
Elisabeth Quoix, Bernard Lebeau, Denis Braun, Jean-Luc Breton, Etienne Lemarié, Sylvie Gouva, …
Elisabeth Quoix, Bernard Lebeau, Denis Braun, Jean-Luc Breton, Etienne Lemarié, Sylvie Gouva, …
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients
T Le Chevalier, R Arriagada, E Quoix… - JNCI: Journal of the …, 1991 - academic.oup.com
We report the results observed in a large, randomized study that compared the effects of
radiotherapy alone (the standard therapy) with those of a combination of radiotherapy and …
radiotherapy alone (the standard therapy) with those of a combination of radiotherapy and …
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 …
E Quoix, G Zalcman, JP Oster, V Westeel, E Pichon… - The Lancet, 2011 - thelancet.com
Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell
lung cancer (NSCLC) in fit, non-elderly adults, but monotherapy is recommended …
lung cancer (NSCLC) in fit, non-elderly adults, but monotherapy is recommended …
Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure
M Oswald-Mammosser, E Weitzenblum, E Quoix… - Chest, 1995 - Elsevier
Prognostic factors in COPD patients receiving long-term oxygen (LTO) therapy were
recently analyzed, but very few studies considered the prognostic value of pulmonary artery …
recently analyzed, but very few studies considered the prognostic value of pulmonary artery …
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
…, PA Ganz, S Kaasa, JL Pater, E Quoix, E Rapp… - The Lancet, 1993 - Elsevier
We did a meta-analysis of all published polychemotherapy vs supportive care clinical trials
in patients with non-resectable non small cell lung cancer. 7 studies with more than 700 …
in patients with non-resectable non small cell lung cancer. 7 studies with more than 700 …
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
D Planchard, TM Kim, J Mazieres, E Quoix… - The Lancet …, 2016 - thelancet.com
Background Activating BRAF V600E (Val600Glu) mutations are found in about 1–2% of
lung adenocarcinomas, which might provide an opportunity for targeted treatment in these …
lung adenocarcinomas, which might provide an opportunity for targeted treatment in these …